[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"inflammation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:inflammation":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,166,0,25,[9,42,68,104,128,159,184,215,235,261,294,314,350,373,400,428,450,472,494,514,536,550,579,600,622],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100054061","oxidative-stress-and-inflammatory-biomarkers-in-gaucher-disease-100054061",false,"NCT02437396","Oxidative Stress and Inflammatory Biomarkers in Gaucher Disease","Novel Inflammatory Biomarkers Complement 5A and Hepcidin in Patients With Gaucher Disease (GD)","Inclusion criteria:\n\n1. All participants must be 18 years or older.\n2. All enrollees must understand and cooperate with requirements of the study in the opinion of the investigators and must be able to provide written informed consent.\n3. Individuals with Gaucher disease who are medically stable for participation in study in the opinion of the investigator.\n4. GD subjects must be stable on a specific ERT and\u002For SRT therapy at a specific dose (for e.g. on a units\u002Fkg basis) for at least 2 years or be naïve to these therapies (no therapy for 2 years).\n5. GD1 patients, who have had a change in therapy i.e. a change in dose or switch from one drug to another, can be enrolled after at least 6 months have elapsed since the change and is considered stable in the opinion of the clinician providing care to the patient.\n6. All participants must not have taken antioxidants coenzyme Q-10, vitamin C, or vitamin E for 3 weeks prior to the study.\n\nExclusion Criteria:\n\n1. Medically unstable conditions in any group as determined by the investigators\n2. Concurrent disease; medical condition; or an extenuating circumstance that, in the opinion of the investigator, might compromise subject safety, study compliance, completion of the study, or the integrity of the data collected for the study.\n3. Females who are pregnant or lactating or of child-bearing age who are not using acceptable forms of contraception\n4. History of asthma that is presently being treated\n5. Subjects who cannot or are unwilling to have blood drawn\n6. Unable to adhere to study protocol for whatever reason","ALL","18 Years","75 Years",{"count":21,"type":22},34,"ESTIMATED","OBSERVATIONAL","The objective of this study is to evaluate oxidative stress and\u002For inflammation in patients with Gaucher disease type I using a series of biomarkers and correlate with measurements of currently used diagnostic biomarkers.",[26,27,28],"Gaucher Disease Type I","Oxidative Stress","Inflammation","RECRUITING","2026-07-10",{"date":32,"type":33},"2026-07-13","ACTUAL",{"date":35,"type":33},"2015-10",{"date":37,"type":22},"2026-10-30",{"name":39,"class":40},"University of Minnesota","OTHER",1,{"id":43,"slug":44,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":12,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":41},"100054284","early-phase-1-metformin-and-aclr-muscle-recovery-100054284","NCT07699367","Metformin and ACLR Muscle Recovery","Metformin and Muscle Recovery Following ACL Surgery","Inclusion Criteria:\n\n1. Age between 40y and older\n2. BMI: \\\u003C30 kg\u002Fm2\n3. Full thickness ACL tear\n4. Less than 6 months between ACL injury and scheduled ACLR\n\nExclusion Criteria:\n\n1. Prior ACL tear in limb scheduled for reconstruction or current bilateral ACL tear\n2. Total knee dislocation\n3. Anticipated quadriceps ACLR grafts\n4. Current infection near the lower limb\n5. Inability to attend physical therapy sessions\n6. Post-operative loading restrictions\n7. History of cardiovascular disease (e.g., CHF, CAD, MI, CVA)\n8. History of endocrine or metabolic disease such as hypo\u002Fhyperthyroidism and diabetes (Treated hypo\u002Fhyperthyroid for at least 6 months will be permitted)\n9. History of stroke with motor disability\n10. History of respiratory disease (acute upper respiratory infection, history of chronic lung disease)\n11. Self-reported pregnancy\n12. Bleeding disorder\n13. Implanted electronic devices (e.g., pacemakers, electronic infusion pumps, stimulators)\n14. Cancer or history of successfully treated cancer (less than 1 year) other than basal cell carcinoma\n15. Chronic systemic corticosteroid use (≥ 2 weeks) within 4 weeks of enrollment and for study duration (intra-articular\u002Ftopical\u002Finhaled therapeutic or physiologic doses of corticosteroids will be permitted)\n16. Androgens or growth hormone within 6 months of enrollment and for study duration (topical physiologic androgen replacement will be permitted)\n17. Currently taking estrogen products (topical estrogen products will be permitted)\n18. Taking anticoagulant medication (warfarin\u002FCoumadin, heparin) that may complicate the muscle biopsy\n19. Any staff members who report directly to the principal investigators","40 Years",{"count":51,"type":22},40,"INTERVENTIONAL",[54],"EARLY_PHASE1","The purpose of this research study is to determine if Metformin taken after anterior cruciate ligament reconstruction (ACLR) surgery can decrease muscle fibrosis, cellular senescence and improve leg strength. ACL injury and surgery increase muscle collagen content and inflammation which slows the recovery of muscle and function and ultimately impacts the quality of life. Individuals enrolled in the study will be randomized to receive metformin (or placebo) for 4 months after surgery. The investigators will measure muscle strength and inflammatory markers in muscle biopsy samples after the intervention period. Investigators will also follow up with participants 8 months later to determine the lasting effects of the intervention.",[57,28,58],"Atrophy","Weakness, Muscle","NOT_YET_RECRUITING","2026-07-09",{"date":32,"type":33},{"date":63,"type":22},"2026-11-01",{"date":65,"type":22},"2032-10-01",{"name":67,"class":40},"University of Utah",{"id":69,"slug":70,"hasResults":12,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":52,"phases":79,"briefSummary":81,"conditions":82,"keywords":86,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":41},"100645108","randomized-cross-over-comparison-of-medium-cut-off-and-high-flux-hemodialysis-membranes-100645108","NCT07679763","Randomized Cross-Over Comparison of Medium Cut-Off and High-Flux Hemodialysis Membranes","Randomized Cross-Over Evaluation of Medium Cut-Off and High-Flux Hemodialysis Membranes on Inflammation and Cardiovascular Function in Maintenance Hemodialysis Patients","MCO-HD","Inclusion Criteria:\n\n* Age 18 to 80 years.\n* Receiving maintenance hemodialysis for at least 6 months.\n* Clinically stable and receiving thrice-weekly hemodialysis.\n* Able to comply with study procedures, questionnaires, and scheduled assessments.\n* Able and willing to provide written informed consent.\n\nExclusion Criteria:\n\n* Acute infection at screening or enrollment.\n* Major surgery within the previous 3 months.\n* Active malignancy requiring ongoing treatment.\n* Terminal illness with limited life expectancy.\n* Physical or cognitive impairment preventing completion of study procedures or questionnaires.\n* Inability or unwillingness to provide written informed consent.","80 Years",{"count":78,"type":22},30,[80],"NA","Patients receiving maintenance hemodialysis are at increased risk of cardiovascular disease, chronic inflammation, endothelial dysfunction, and impaired quality of life. Medium cut-Off (MCO) hemodialysis membranes have been developed to enhance the removal of middle-molecular-weight uremic toxins compared with conventional high-flux membranes, which may improve inflammatory status and cardiovascular health.\n\nThe aim of this study is to compare the effects of MCO and high-flux hemodialysis membranes on inflammatory biomarkers and cardiovascular function in adult patients receiving maintenance hemodialysis. The primary outcomes are changes in serum interleukin-6 (IL-6) and vascular cell adhesion molecule-1 (VCAM-1) levels. Secondary outcomes include arterial stiffness assessed by pulse wave velocity (PWV), body composition assessed by Body Composition Monitor (BCM), handgrip strength, and patient-reported outcomes including quality of life, pruritus, and pain scores.\n\nThis is a prospective, randomized, open-label, two-sequence, two-period crossover study conducted at Gazi University Faculty of Medicine. Thirty adult hemodialysis patients will be randomized to one of two treatment sequences. Participants in Sequence A will receive MCO dialysis membranes for the first 3 months followed by high-flux membranes for the next 3 months. Participants in Sequence B will receive high-flux membranes for the first 3 months followed by MCO membranes for the next 3 months. Blood samples and clinical assessments will be performed at baseline, month 3, and month 6.\n\nThe study is expected to provide evidence regarding the effects of different dialysis membrane technologies on inflammation and cardiovascular health and may contribute to optimizing membrane selection in routine hemodialysis practice.",[83,84,85,28],"End Stage Kidney Disease (ESKD)","Hemodialysis","Cardiovascular Diseases (CVD)",[87,88,89,90,91,28,92,93,94],"End-Stage Kidney Disease","High-Flux Hemodialysis","Medium Cut-Off Membrane","Interleukin-6","VCAM-1","Cardiovascular Function","Pulse Wave Velocity","Body Composition Monitor","2026-06-30",{"date":97,"type":33},"2026-07-01",{"date":99,"type":22},"2026-07",{"date":101,"type":22},"2027-01",{"name":103,"class":40},"Gazi University",{"id":105,"slug":106,"hasResults":12,"nctId":107,"briefTitle":108,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":12,"sex":17,"minAge":110,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":114,"conditions":115,"keywords":117,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":4,"leadSponsor":125,"locationsCount":41},"100099544","diagnosis-and-management-of-inflammatory-and-infectious-diseases-100099544","NCT00557726","Diagnosis and Management of Inflammatory and Infectious Diseases","* INCLUSION CRITERIA:\n\n  1. Known or suspected exposure to infection, as determined by the Principal Investigator OR Presence of signs and symptoms of an infectious or inflammatory disease\n  2. Age range: 3 years of age and older.\n  3. NIAID\u002FLIR investigator who has an interest in the patient s illness and is willing to serve as attending physician to supervise the patient's medical care at the NIH.\n  4. Primary physician outside the NIH\n  5. The patient or the patient's Legally Authorized Representative is capable of informed consent and signs the consent form. The consent form will be signed by parents or guardians of patients under the age of 18\n\nEXCLUSION CRITERIA:\n\n1. Pregnant.\n2. Presence of conditions that, in the judgment of the investigator, may put the participant at undue risk or make them unsuitable for participation in the study.","3 Years","100 Years",{"count":113,"type":22},400,"This protocol is being established to cover the evaluation of patients with inflammatory and\u002For infectious diseases which are not covered under previously existing protocols. The purpose of such a protocol is that frequently patients are referred to us with either diagnosed or undiagnosed illnesses which would be of interest to our teaching program or which would serve as a source of patients to subsequently be entered into established, ongoing protocol studies. Such patients will be admitted to the protocol and handled according to accepted medical practice of diagnosis and treatment.",[116,28],"Infection",[28,116,118,119],"Fever","Natural History","2026-06-24",{"date":122,"type":33},"2026-06-25",{"date":124,"type":33},"1978-02-17",{"name":126,"class":127},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH",{"id":129,"slug":130,"hasResults":12,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":136,"sex":17,"minAge":137,"maxAge":138,"enrollmentInfo":139,"targetDuration":4,"studyType":52,"phases":141,"briefSummary":142,"conditions":143,"keywords":146,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":41},"100643987","independent-and-combined-effects-of-short-term-sulforaphane-supplementation-and-exercise-on-immunometabolism-in-healthy-adults-100643987","NCT07668596","Independent and Combined Effects of Short-term Sulforaphane Supplementation and Exercise on Immunometabolism in Healthy Adults","Independent and Combined Effects of Short-term Sulforaphane Supplementation and Exercise on Immunometabolism in Healthy Adults: A Randomized Crossover Study","EXSFN","Inclusion Criteria:\n\n* aged between 18 and 35 years\n* not a current smoker\n* physically active based on the Canadian Physical Activity Guidelines (150 minutes of weekly physical activity)\n\nExclusion Criteria:\n\n* a history of cardiometabolic diseases or respiratory diseases (e.g., chronic obstructive pulmonary disease, asthma, diabetes, coronary artery disease)\n* currently following a ketogenic diet\n* body mass index (BMI) over 30 kg\u002Fm2\n* unable to read or communicate in English\n* having received a vaccination or experienced an upper respiratory tract infection in the last 4 weeks\n* having donated more than 0.5 L of blood within the last 4 weeks\n* currently pregnant\n* have contraindications to high intensity exercise (assessed using the CSEP Get Active Questionnaire)",true,"19 Years","35 Years",{"count":140,"type":22},20,[80],"The study consist of 3 interventional periods which will be completed by each consenting participant in a randomized, crossover fashion. The interventional periods will be separated by a minimum 1 week washout period. One of the interventions consists of 4 days of daily supplementation with the commercially available broccoli sprout extract capsules (BrocElite). Another intervention will consist of 4 days of daily supervised treadmill running. The exercise protocol consists of 4 minutes of high-intensity running running followed by a 3 minute recovery period, repeated for a total of 4 repetitions. The last intervention combines the above two and consists of 4 days of daily supplementation and daily supervised exercise training. Before and after each intervention, basic anthropometrics (weight, heart rate, and blood pressure) will be recorded, and a venous blood sample will be collected. Blood samples will be analyzed for metabolic and inflammatory markers. Participants will be asked to refrain from structured exercise, alcohol consumption, and broccoli consumption during each of the experimental periods. Before any testing, willing participants will provide informed consent, and fill out a few demographic, and lifestyle questionnaires. The study will be conducted at the University of British Columbia in Kelowna, BC, Canada.",[144,145,28],"Immunometabolism","Mitochondrial Function, Bioenergetics",[147,148,149,144,28,150],"Nutraceuticals","Exercise","Bioenergetics","High intensity interval training","2026-06-19",{"date":122,"type":33},{"date":154,"type":33},"2026-03-01",{"date":156,"type":22},"2028-06-01",{"name":158,"class":40},"University of British Columbia",{"id":160,"slug":161,"hasResults":12,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":166,"enrollmentInfo":167,"targetDuration":4,"studyType":52,"phases":169,"briefSummary":171,"conditions":172,"keywords":174,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":41},"100590545","phase-3-study-on-ketorolac-for-improving-outcomes-and-prognosis-in-patients-with-stanford-type-a-aortic-dissection-100590545","NCT06968806","Study on Ketorolac for Improving Outcomes and Prognosis in Patients With Stanford Type A Aortic Dissection","Study on Ketorolac for Improving Outcomes and Prognosis in Patients With Stanford Type A Aortic Dissection -A Single-Center, Randomized, Double-Blind, Controlled Clinical Trial","Inclusion Criteria:\n\n* Patients with Stanford Type A aortic dissection confirmed by imaging and scheduled for emergency surgery.\n\nAged between 18 and 65 years.\n\nSigned informed consent.\n\nExclusion Criteria:\n\n* Patients who are unable to eat independently or require prolonged fasting.\n\nHistory of malignant tumors.\n\nBody weight \\\u003C50 kg.\n\nTraumatic aortic dissection.\n\nPatients with Marfan syndrome.\n\nUnstable vital signs requiring preoperative mechanical support or resuscitation (e.g., IABP \\[Intra-Aortic Balloon Pump\\], ECMO \\[Extracorporeal Membrane Oxygenation\\], LVAD \\[Left Ventricular Assist Device\\])\n\nPatients requiring preoperative endotracheal intubation.\n\nConsciousness impairment, central nervous system dysfunction, or evidence of cerebral malperfusion syndrome upon admission.\n\nPreoperative hematemesis, melena, fresh blood in stool, or symptoms of bowel dilation.\n\nClear evidence of limb malperfusion before surgery.\n\nPresence of organ malperfusion syndrome.\n\nPatients requiring interventional procedures to relieve organ malperfusion before surgery.\n\nHistory of gastrointestinal ulcers or chronic gastrointestinal inflammatory diseases.\n\nHistory of dialysis or renal insufficiency before admission.\n\nHistory of liver disease.\n\nAllergy to ketorolac tromethamine, aspirin, or other nonsteroidal anti-inflammatory drugs (NSAIDs).\n\nChronic inflammatory diseases, autoimmune diseases, or long-term use of steroids or NSAIDs for other reasons.\n\nAbsence of cerebral perfusion during deep hypothermic circulatory arrest.\n\nHistory of major surgery or acute myocardial infarction within 90 days.\n\nHistory of cardiac or major vascular surgery.\n\nPregnant or lactating women.\n\nPatients who refuse to participate in this clinical trial or decline to sign the informed consent form.\n\nAny other conditions deemed unsuitable for participation by the investigator.","65 Years",{"count":168,"type":22},360,[170],"PHASE3","This multicenter, randomized, double-blind, placebo-controlled trial evaluates the efficacy and safety of ketorolac in 360 patients with Stanford Type A aortic dissection, conducted between 2025 and 2027. Participants will receive either ketorolac (60 mg intramuscularly \\[IM\\] preoperatively and 30 mg twice daily \\[BID\\] for two days postoperatively) or placebo in addition to standard care. Study outcomes include composite clinical endpoints, postoperative complications, and adverse events, which will be assessed through clinical evaluations, laboratory testing, and imaging studies at predefined intervals up to 90 days. The objective of this trial is to determine whether perioperative administration of ketorolac improves clinical outcomes in this patient population.",[173,28],"Aortic Dissection",[28,173,175],"Ketorolac",{"date":177,"type":33},"2026-06-23",{"date":179,"type":33},"2025-10-27",{"date":181,"type":22},"2028-09-01",{"name":183,"class":40},"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School",{"id":185,"slug":186,"hasResults":12,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":190,"eligibilityCriteria":191,"healthyVolunteers":136,"sex":17,"minAge":192,"maxAge":193,"enrollmentInfo":194,"targetDuration":4,"studyType":52,"phases":196,"briefSummary":197,"conditions":198,"keywords":203,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":41},"100582854","ketone-ester-and-salt-keas-in-older-adults-100582854","NCT06868719","Ketone Ester And Salt (KEAS) in Older Adults","Ketone Supplementation as a Strategy to Reduce the Negative Health Effects of High Dietary Salt in Older Adults","KEAS-O","Inclusion Criteria:\n\n* Between the ages of 60-85\n* Resting blood pressure no higher than 150\u002F90\n* BMI below 35 kg\u002Fm2 (or otherwise healthy)\n* Free of any metabolic disease (diabetes or renal), pulmonary disorders (COPD, severe asthma, or cystic fibrosis), cardiovascular disease (peripheral vascular, cardiac, or cerebrovascular)\n* Do not have any precluding medical conditions that prevent participants from exercising (i.e., cardiovascular issues, or muscle\u002Fjoint issues including painful arthritis) or giving blood (e.g., blood thinners)\n\nExclusion Criteria:\n\n* High blood pressure - greater than150\u002F90 mmHg\n* Obesity (BMI \\> 30 kg\u002Fm2)\n* History of metabolic disease (diabetes or renal disease), pulmonary disorders (e.g., COPD, severe asthma, \\& cystic fibrosis), and cardiovascular disease (peripheral vascular, cardiac, or cerebrovascular).\n* Medical issues that prevent safe exercise (i.e., cardiovascular issues, or muscle\u002Fjoint issues including painful arthritis)\n* Medical issues that prevent giving blood (e.g., blood thinners).\n* Current smoking, using smokeless tobacco, or vaping (within past 12 months)\n* Current pregnancy","50 Years","85 Years",{"count":195,"type":22},35,[80],"Most Americans consume excess dietary salt based on the recommendations set by the American Heart Association and Dietary Guidelines for Americans. High dietary salt impairs blood pressure control by affecting systemic blood vessels and the kidneys. These changes contribute to excess salt consumption being associated with increased risk for chronic kidney disease and cardiovascular disease, the leading cause of death in America. Salt is particularly deleterious in older adults who are more likely to exhibit salt-sensitive hypertension. However, salt consumption remains high in the United States. Thus, there is a critical need for strategies to counteract the effects of high dietary salt as consumption is likely not going to decrease. One promising option is ketones, metabolites that are produced in the liver during prolonged exercise and very low-calorie diets. While exercise and low-calorie diets are beneficial, not many people engage in these activities. Limited evidence indicates that ketone supplements improve cardiovascular health in humans. Additionally, published rodent data indicates that ketone supplements prevent high salt-induced increases in blood pressure, blood vessel dysfunction, and kidney injury. Our human pilot data also indicates that high dietary salt reduces intrinsic ketone production, but it is unclear whether ketone supplementation confers humans' protection against high salt similar to rodents. Therefore, the investigators seek to conduct a short-term high-dietary salt study to determine whether ketone supplementation prevents high dietary salt from eliciting increased blood pressure, blood vessel dysfunction, and kidney injury\u002Fimpaired blood flow. The investigators will also measure inflammatory markers in blood samples and isolate immune cells that control inflammation. Lastly, the investigators will also measure blood ketone concentration and other circulating metabolites that may be altered by high salt, which could facilitate novel therapeutic targets to combat high salt.",[199,200,201,28,202],"Salt; Excess","Hypertension","Aging","Blood Pressure",[202,204,201,28,205],"Salt","Cardiovascular Disease","2026-06-16",{"date":208,"type":33},"2026-06-18",{"date":210,"type":33},"2025-03-06",{"date":212,"type":22},"2027-12-31",{"name":214,"class":40},"Indiana University",{"id":216,"slug":217,"hasResults":12,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":4,"eligibilityCriteria":221,"healthyVolunteers":136,"sex":17,"minAge":18,"maxAge":166,"enrollmentInfo":222,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":224,"conditions":225,"keywords":226,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":231,"completionDateStruct":4,"leadSponsor":233,"locationsCount":41},"100087476","immune-cell-response-to-stimuli-100087476","NCT00397280","Immune Cell Response to Stimuli","Innate Immunity Signal Transduction in Human Leukocytes","* INCLUSION CRITERIA:\n* Normal, healthy adult donors as judged by screening questionnaire\n* Nonpregnant\n* Weighing at least 110 lbs\n* 18-65 years of age\n* HIV negative (proof required every 6 months we will conduct test)\\*\n* Hepatitis B surface antigen and hepatitis C serology negative (checked every 6 months we will conduct test)\\*\n\n  * The rationale for HIV and hepatitis viral testing is that chronic viral infection may alter and possibly invalidate our experimental results. HIV and hepatitis results will be confidentially obtained. Testing will be contracted to an external certified laboratory and will be paid for by the study group. Results will be available only to the study doctor\u002FPI (Fessler), the study coordinator, the CRU Director (Garantziotis, LAI), and the donor, with the few caveats that follow\n\nAll positive HIV, hepatitis B, and hepatitis C results will be promptly communicated to the donor by the study doctor\u002FPI or the CRU Director. The participant will be referred to their physician and\u002For to the N.C. Department of Health for confirmatory testing and counseling. As explained in detail in the attached Supplement describing N.C. State Department of Health code will be followed. The state code mandates reporting of positive results along with the participant s name and identifying information to the N.C. Department of Public Health. Upon contracting with the testing laboratory, clarification will be obtained and documented as to whether the contracted laboratory or the study MD will be responsible for reporting positive results to the state to avoid duplication of reporting. Upon receipt of the test results, the N.C. Department of Health will contact the participant to inform them of the positive result, how to find care, how to avoid infecting others, how the newly diagnosed HIV and\u002For hepatitis infection is reported, and the importance of informing their partners at possible risk because of their HIV and\u002For hepatitis infection. If the HIV, hepatitis B, and hepatitis C results are negative, the participant will be not be notified. However, the participant may contact the research study nurse for their results.\n\nHIV and hepatitis B\u002FC test results, non-reactive and reactive, will be documented confidentially by the PI or study coordinator in the subject s file, and kept in a locked file cabinet in the CRU Medical Records Room.In order to document the reporting procedure and the time associated with the reporting process, a document has been created and placed in the study specific manual (Hepatitis B\u002FC and HIV Notification Process for Reactive Results Form)\n\nEXCLUSION CRITERIA:\n\nBy questionnaire:\n\nFeeling ill within the last 24 hours.\n\nAlcohol consumption in the last 24 hours.\n\nVisit to the dentist in the last 24 hours.\n\nA doctor visit for illness or vaccination in the last 2 weeks.\n\nDiarrhea in the last 2 weeks.\n\nRecurrent fever (4 weeks).\n\nPregnant or suspected pregnancy in the last 6 weeks.\n\nBlood or plasma donation that will cause the participant to exceed 550ml of blood in the last 8 weeks.\n\nReceiving a blood donation in the past 12 months.\n\nBleeding disorder.\n\nAnemia.\n\nHeart problems.\n\nInsulin dependent diabetes.\n\nProblems with blood donation.\n\nRisk of or evidence of Creutzfeldt-Jacob Disease in the family.\n\nHIV-positive status, Hepatitis B\u002FC-positive status or other confirmed or suspected immunosuppressive or immunodeficient conditions.\n\nUse of immunosuppressants or other immune-modifying drugs.\n\nUse of selected medications within the preceding 5 days unless the PI or AI receiving the samples states otherwise (NSAIDS\u002Faspirin\u002Ftylenol, antidepressants, antihistamines , corticosteroids, HMG CoA reductase inhibitors, and antihypertensives).\n\nBy exam:\n\nTemperature over 99.5 F.\n\nBlood pressure less than 90\u002F50.\n\nBlood pressure higher than 170\u002F95 mm Hg.\n\nPulse rate less than 50 or greater than 100 beats\u002Fminute.\n\nIf blood donation exceeds 200ml:\n\n* Hematocrit less than 34% for women or less than 36% for men, or greater than 56% for either gender.\n* Patients will be informed of disqualifying vital signs and hematocrit values and advised by trained staff, as appropriate, to seek assistance from their physician.",{"count":223,"type":22},750,"This study will investigate the response of immune cells (neutrophils, monocytes) to various signals in the test tube to determine how they sense the signals in the body and what substances they produce in response to them. It will determine how the cells may, under certain circumstances, contribute to inflammation, and will measure substances in the blood plasma (the liquid, non-cellular part of the blood) that might stimulate white blood cells, in order to understand how the blood responds to possible disease-related conditions.\n\nHealthy normal volunteers 18 years of age and older who weigh at least 110 pounds may be eligible for this study. Participants give about 320 milliliters (mL) of blood (about 1 1\u002F3 cups) or less at each donation. They donate no more than once every 8 weeks and no more than six times a year. On some occasions, less than 320 mL of blood may be drawn. The collected blood is separated into its components and specific cells are exposed to substances to examine their response.",[28],[227,228,119],"Inflammatory Response","Lipopolysaccharide","2026-06-13",{"date":206,"type":33},{"date":232,"type":33},"2009-07-13",{"name":234,"class":127},"National Institute of Environmental Health Sciences (NIEHS)",{"id":236,"slug":237,"hasResults":12,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":4,"eligibilityCriteria":241,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":242,"targetDuration":244,"studyType":23,"phases":4,"briefSummary":245,"conditions":246,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":259,"locationsCount":4},"100642567","effects-of-icosapent-ethyl-on-coronary-plaque-inflammation-and-ventricular-remodeling-100642567","NCT07641257","Effects of Icosapent Ethyl on Coronary Plaque, Inflammation, and Ventricular Remodeling","Impact of Icosapent Ethyl on Ventricular Remodeling, Inflammation, and Coronary Plaque Stability in Patients With Acute or Chronic Coronary Syndrome: A Prospective, Observational, Real-World Study","Inclusion Criteria:\n\n* Age 18 years and older, of any sex.\n\n  * Definite diagnosis of chronic coronary syndrome (CCS) according to the Chinese Guidelines for the Diagnosis and Management of Patients with Chronic Coronary Syndrome, or acute coronary syndrome (ACS) according to the 2025 ACC\u002FAHA\u002FACEP\u002FNAEMSP\u002FSACI Guideline for the Management of Acute Coronary Syndromes.\n  * Laboratory evaluation showing fasting triglycerides (TG) \\>= 1.7 mmol\u002FL.\n  * Ability to fully understand the study purpose, voluntary participation, and provision of signed written informed consent.\n\nExclusion Criteria:\n\n* Women who are planning a pregnancy, currently pregnant, or lactating.\n\n  * Known hypersensitivity or allergic reaction to the active ingredient of icosapent ethyl (IPE) or any of its excipients (applicable to patients in the exposure cohort).\n  * Diagnosed with major life-threatening conditions such as malignant tumors, end-stage lung disease, or advanced neurodegenerative diseases, with a life expectancy of less than 12 months.\n  * Concurrent participation in any other interventional clinical trial involving investigational drugs or medical devices.\n  * Any other condition or severe non-compliance that, in the judgment of the investigator, makes the patient unsuitable for enrollment in this study.",{"count":243,"type":22},420,"12 Months","Even with standard treatments like statins, patients with coronary artery disease often face a residual risk of further heart events. This risk is largely driven by ongoing inflammation and unstable fatty plaques in the heart's blood vessels. Icosapent ethyl (IPE) is a highly purified prescription medication known to improve cardiovascular outcomes, but its detailed effects on the heart's structure and inflammation in everyday clinical practice need further exploration.\n\nThis study is a prospective, observational, real-world study designed to evaluate the effectiveness of IPE in patients with Acute Coronary Syndrome (ACS) or Chronic Coronary Syndrome (CCS). The study plans to enroll 420 patients who will be followed for 12 months. Based on their routine clinical prescriptions, participants will be grouped into a control group (receiving standard cardiovascular care, including statins) and an exposure group (receiving standard care plus IPE).\n\nThroughout the 1-year follow-up, researchers will conduct regular blood tests and advanced heart imaging. The main goal is to determine if adding IPE to standard therapy leads to a more significant reduction in inflammation. Additionally, the study will observe how IPE affects the stability of coronary plaques and the healing process of ventricular remodeling in a real-world clinical setting.",[247,248,249,250,251,28],"Acute Coronary Syndromes (ACS)","Chronic Coronary Syndrome","Coronary Artery Disease","Atherosclerosis Cardiovascular Disease","Ventricular Remodeling","2026-06-08",{"date":254,"type":33},"2026-06-11",{"date":256,"type":22},"2026-05-30",{"date":258,"type":22},"2029-05-30",{"name":260,"class":40},"Ruijin Hospital",{"id":262,"slug":263,"hasResults":12,"nctId":264,"briefTitle":265,"officialTitle":266,"acronym":267,"eligibilityCriteria":268,"healthyVolunteers":136,"sex":269,"minAge":270,"maxAge":166,"enrollmentInfo":271,"targetDuration":4,"studyType":52,"phases":273,"briefSummary":274,"conditions":275,"keywords":278,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":41},"100556603","nitrate-exercise-and-vascular-function-in-midlife-women-100556603","NCT06527248","Nitrate, Exercise and Vascular Function in Midlife Women","Effects of Dietary Nitrate From Beetroot Juice on Vascular Function and Adaptations to Exercise Training in Postmenopausal Women: a Randomized, Placebo-controlled Study","Women's-Beet","Inclusion Criteria:\n\n* Postmenopausal women (amenorrhoeic ≥1 year), between the ages of 45 and 65 years, inclusive, who are either normotensive or are medically treated for stage 1 hypertension\n* Written informed consent\n\nExclusion Criteria:\n\n* Current or recent (within previous 3 months) engagement in exercise training (i.e., planned, structured, and regular exercise) with an average net exercise time of \\>2 hours per week\n* Above-average cardiorespiratory fitness levels (i.e., a V̇O2 max max above the 75th percentile of age- and sex-specific normative data: ≥43 mL\u002Fkg\u002Fmin for women aged 45-49 years, ≥38 mL\u002Fkg\u002Fmin for women aged 50-59 years, ≥35 mL\u002Fkg\u002Fmin for women aged 60-65 years)\n* Any evidence of acute or chronic diseases such as symptomatic cardiovascular or peripheral vascular disease, moderate or severe chronic kidney disease (estimated glomerular filtration rate (GFR) \\\u003C50 mL\u002Fmin), pulmonary, neural, or musculoskeletal disease, osteoporotic fractures, cancer, or type 1 or 2 diabetes mellitus\n* Fasting glucose \\>7.0 mmol\u002FL or HbA1c \\> 6.5 rel. %\n* BMI \\\u003C18.5 kg\u002Fm2 or \\>30kg\u002Fm2\n* A mean 24-hour ambulatory systolic\u002Fdiastolic blood pressure of ≥130\u002F80 mm Hg\n* Irregular resting electrocardiography (ECG)\n* Inability to perform physical exercise\n* Abnormal cardiovascular responses during the baseline V ̇O2 max test, including symptoms, ECG abnormalities, arrhythmias, or exaggerated blood pressure responses\n* Current or recent (\\\u003C12 months) oestrogen-based hormone-replacement therapy\n* Chronic use of nitric oxide (NO) donors, organic nitrites\u002Fnitrates, Ticagrelor, sodium-glucose cotransporter 2 (SGLT2) inhibitors, high-dose statins (i.e., Simvastatin \\>40mg\u002Fday, Atorvastatin \\>20mg\u002Fday, Rosuvastatin \\>10mg\u002Fday), acetylsalicylic acid \\>100mg\u002Fday, non-steroidal anti-inflammatory drugs (NSAID)\n* A change in drug therapy likely to influence major outcomes within the previous 2 months, or likelihood that drug therapy would change during the study\n* Use of antibiotics (within previous 2 months)\n* Use of antibacterial mouthwash (volunteers willing to cease using antibacterial mouthwash for a period of 4 weeks before randomization will be included)\n* Being vegan or vegetarian or consumption of \\>5 serves of vegetables per day\n* Current or recent (within previous 6 months) significant (\\>6%) loss or gain of body weight\n* Current or recent (\\\u003C12 months) regular smoking of \\>5 cigarettes per day\n* Alcohol intake of \\>70 g per week and\u002For binge drinking behaviour\n* Inability or unwillingness to follow the study protocol","FEMALE","45 Years",{"count":272,"type":22},54,[80],"The purpose of this clinical study in women after menopause is to investigate whether the daily intake of nitrate from beetroot juice over 12 weeks enhances the positive effect of exercise training on vascular function, blood pressure and physical performance.\n\nThe risk of cardiovascular diseases (CVD) increases with advancing age and women are particularly affected. In women, the decline in the sex hormone oestrogen in the blood circulation with menopause contributes to impaired vascular function and an increased CVD risk; in part through increased inflammatory processes, oxidative stress, and a reduced body's own production of nitric oxide (NO). NO is a signaling molecule that is important for vascular function. Endurance-based exercise training is a key lifestyle strategy to prevent CVD. However, studies indicate that exercise is less effective in terms of its health-promoting adaptations in women after menopause as compared with men of similar age.\n\nThis study investigates the effect of exercise training in combination with the intake of nitrate-rich beetroot juice on functions of the cardiovascular system. Nitrate is a nitrogen compound that is found naturally in plant foods (e.g. beetroot juice) and is converted to NO in the human body. Results of previous studies indicate vasodilatory, blood pressure-lowering and performance-enhancing effects as well as positive influences on inflammatory processes and oxidative stress following nitrate intake. The hypothesis is that nitrate intake concomitant to training promotes training adaptations and further improves vascular function, blood pressure and physical performance compared to training without nitrate intake.\n\nFor the study, 54 untrained postmenopausal women (with the ages between 45 and 65 years) will be recruited and randomly allocated into two groups. Both groups will undergo 12 weeks of endurance-based exercise training. One group will receive nitrate-rich beetroot juice, and the other nitrate-depleted beetroot juice (as placebo). Vascular function, blood pressure, maximum oxygen uptake, and blood biomarkers for nitrate metabolism, inflammation status and oxidative stress will be examined.\n\nThe anticipated study results will provide new insights into whether nitrate as a 'training adjunct' improves health-promoting training adaptations in women after menopause. The overall aim is to improve the cardiovascular health and performance of middle-aged women and reduce their increased CVD risk.",[276,277,200,28],"Healthy","Menopause",[279,280,281,282,283,284],"Women after menopause","Vascular function","Exercise training responsiveness","Cardiovascular health","Dietary nitrate-nitrite-nitric oxide-pathway","Beetroot juice","2026-06-03",{"date":287,"type":33},"2026-06-05",{"date":289,"type":33},"2025-03-31",{"date":291,"type":22},"2027-03",{"name":293,"class":40},"University of Vienna",{"id":295,"slug":296,"hasResults":12,"nctId":297,"briefTitle":298,"officialTitle":298,"acronym":4,"eligibilityCriteria":299,"healthyVolunteers":136,"sex":17,"minAge":300,"maxAge":166,"enrollmentInfo":301,"targetDuration":4,"studyType":52,"phases":302,"briefSummary":303,"conditions":304,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":312,"locationsCount":41},"100400646","pilot-study-evaluating-the-impact-of-stress-reduction-on-atherosclerotic--heart-and-mind-study-100400646","NCT04496947","Pilot Study Evaluating the Impact of Stress Reduction on Atherosclerotic : Heart and Mind Study","Inclusion Criteria:\n\n* • Aged between 30-65 years\n\n  * Identifies as having increased levels of stress and\u002For has a Perceived Stress Scale (PSS) score \\>5 at baseline, and is interested in participating\n\nExclusion Criteria:\n\n* Perceived Stress Scale (PSS) score \\\u003C6","30 Years",{"count":78,"type":22},[80],"The plot study aims to evaluate the effect of 8 weeks of stress reducing intervention on atherosclerotic plaque inflammation in adults, as quantified by positron emission tomography (PET) with fluorine-2-deoxy-D-glucose (FDG) in individuals with increased psychosocial stress.",[305,306,28],"Atherosclerosis","Stress","2026-05-31",{"date":285,"type":33},{"date":310,"type":33},"2018-09-01",{"date":212,"type":22},{"name":313,"class":40},"Massachusetts General Hospital",{"id":315,"slug":316,"hasResults":12,"nctId":317,"briefTitle":318,"officialTitle":319,"acronym":320,"eligibilityCriteria":321,"healthyVolunteers":136,"sex":269,"minAge":18,"maxAge":322,"enrollmentInfo":323,"targetDuration":4,"studyType":52,"phases":325,"briefSummary":327,"conditions":328,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":342,"startDateStruct":344,"completionDateStruct":346,"leadSponsor":348,"locationsCount":41},"100640820","phase-1-hormones-outcomes-and-pain-pathways-in-exercise-study-100640820","NCT07579182","Hormones, Outcomes, and Pain Pathways in Exercise Study","Mechanical and Non-mechanical Contributions to Chronic Neck, Shoulder, Arm, and Back Pain in Full-busted Women","HOPE","Inclusion Criteria:\n\n1. Able to provide informed consent\n2. Age of 18 to 60 years\n3. Assigned female sex at birth\n4. Right-handed by self-declaration\n5. Willing to participate in one online testing session and up to four in-person testing sessions\n6. Bra band size between 32-40\"\n7. International Physical Activity Questionnaire - Short Form (IPAQ-SF) score of 2 or higher\n8. An answer of \"NO\" to any item of the general health questions of the PARQ+\n9. No history of surgery to the: back, neck, or shoulders or joint replacement\n10. No history of implanted pacemakers or other stimulation devices\n11. No history of spinal cord injury (SCI)\n\nExclusion Criteria:\n\n1. Inability to provide informed consent\n2. Age 17 years old or younger or 61 years or older\n3. Assigned male sex at birth\n4. Left-handed by self-declaration\n5. Not willing to participate in one online testing session and up to four in-person testing sessions\n6. Bra band size greater than 40\" or less than 32\"\n7. IPAQ-SF score of 1 or lower\n8. An answer of \"YES\" to any item of the general health questions of the PARQ+\n9. History of limb amputation (upper or lower extremity)\n10. Presence of open pressure sores on the upper or lower extremities\n11. Currently pregnant or lactating\u002Fbreastfeeding\n12. History of surgery to the: back, neck, or shoulders or joint replacement\n13. History of breast cancer and\u002For mastectomy\n14. History of implanted pacemakers or other stimulation devices\n15. History of spinal cord injury (SCI)\n16. History of joint disease including osteoarthritis and\u002For Rheumatoid Arthritis\n17. History of the following neurological diseases: Cerebrovascular accident (CVA, stroke), Alzheimer's Disease (AD), Dementia (of any form), Huntington's Disease, Traumatic Brain Injury (TBI), Spinal cord injury (SCI), Multiple Sclerosis (MS), Parkinson's Disease (PD), Polio, Paraproteinaemic Demyelinating Neuropathy (PDN) and\u002For Monoclonal Gammopathy of Undetermined Significance (MGUS), Myasthenia Gravis, Muscular Dystrophy, Guillain-Barré Syndrome, Scoliosis, Charcot-Marie-Tooth Disorder or other hereditary neuropathies\n\nAdditional Inclusion Criteria for Intervention Group:\n\na. Self-declared breast size of D-I cup (US sizes: D, E, F, G, H)\n\nAdditional Inclusion Criteria for the Control Group:\n\na. Self-declared breast size of A-C cup (US sizes: AA, A, B, C)","60 Years",{"count":324,"type":22},140,[326],"PHASE1","The goal of the proposed project is to evaluate a mechanical intervention (sports bras designed specifically for full busted women) to alleviate neck, shoulder, arm, and back pain in full-busted women and investigate the contribution of non-mechanical pathways associated with this type of pain in women. Specifically, the investigators will investigate how sex-hormones, inflammation, and remapping of specific regions of the brain contribute to the manifestation of neck, shoulder, arm, and back pain in full-busted women across the lifespan.",[329,330,331,332,333,334,335,336,337,28,338,339,340],"Breast Pain","Mastalgia","Back Pain","Back Pain, Low","Neck Pain","Chest Pain","Activity, Motor","Healthy Aging","Weight, Body","Gonadal Steroid Hormones","Neuronal Plasticity","Neuromuscular Manifestations","2026-05-28",{"date":343,"type":33},"2026-06-02",{"date":345,"type":33},"2026-05-17",{"date":347,"type":22},"2029-09",{"name":349,"class":40},"University of Houston",{"id":351,"slug":352,"hasResults":12,"nctId":353,"briefTitle":354,"officialTitle":354,"acronym":4,"eligibilityCriteria":355,"healthyVolunteers":136,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":356,"targetDuration":4,"studyType":52,"phases":358,"briefSummary":359,"conditions":360,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":363,"lastUpdatePostDateStruct":364,"startDateStruct":366,"completionDateStruct":368,"leadSponsor":370,"locationsCount":41},"100640688","clinical-trial-evaluating-the-impact-of-a-dietary-supplement-containing-humic-and-fulvic-acid-on-epigenetic-markers-of-biological-age-detoxification-inflammation-and-oxidative-stress-100640688","NCT07579845","Clinical Trial Evaluating the Impact of a Dietary Supplement Containing Humic and Fulvic Acid on Epigenetic Markers of Biological Age, Detoxification, Inflammation, and Oxidative Stress","Inclusion Criteria:\n\n1. Adult females or males age ≥ 40 years\n2. Ability to read and speak English\n\nExclusion Criteria:\n\n1. Current use of a dietary supplement containing fulvic or humic acid\n2. Current use of other binder dietary supplements, including activated charcoal, modified citrus pectin, bentonite clay, or chlorella\n3. Known allergies to any ingredients in the product\n4. Currently pregnant or lactating women or women planning to become pregnant in the next 12 weeks\n5. Current diagnosis of a chronic health condition (e.g., cancer, heart failure, history of pancreatitis, type I or II diabetics on insulin) deemed clinically contraindicated for the study protocol\n6. Participants unable to provide consent",{"count":357,"type":22},60,[80],"The primary purpose of this study is to evaluate the impact of BioToxin Binder, a commercially available dietary supplement containing humic and fulvic acid, on markers of biologic age, detoxification, inflammation, oxidative stress, and related markers among generally healthy adults.",[361,28,362],"Detoxification","Biological Aging","2026-05-27",{"date":365,"type":33},"2026-05-29",{"date":367,"type":33},"2026-05-05",{"date":369,"type":22},"2026-09",{"name":371,"class":372},"OvationLab","NETWORK",{"id":374,"slug":375,"hasResults":12,"nctId":376,"briefTitle":377,"officialTitle":377,"acronym":4,"eligibilityCriteria":378,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":379,"targetDuration":4,"studyType":52,"phases":380,"briefSummary":382,"conditions":383,"keywords":387,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":392,"lastUpdatePostDateStruct":393,"startDateStruct":395,"completionDateStruct":396,"leadSponsor":398,"locationsCount":41},"100639675","phase-2-effect-of-an-isolevuglandin-scavenger-on-salt-sensitivity-of-blood-pressure-and-immune-cell-activation-in-humans-100639675","NCT07602166","Effect of an Isolevuglandin Scavenger on Salt Sensitivity of Blood Pressure and Immune Cell Activation in Humans","Inclusion Criteria:\n\n* We will perform analyses in participants previously phenotyped for SSBP, defined as a change in systolic blood pressure ≥10 mmHg from salt-loading to salt-depletion,\n* Over 18 years of age. Able to give informed consent,\n\nExclusion criteria:\n\n* Salt-resistant people,\n* Acute cardiovascular event(s) within the previous 6 months,\n* inability to understand the nature, scope, and possible consequences of the study or to participate in\u002Fcomply with the protocol,\n* Current excessive alcohol or illicit drug use,\n* BP below the inclusion criteria levels after discontinuation of therapy,\n* Concomitant diabetes mellitus, type I or II,\n* Autoimmune disease,\n* Recent vaccination,\n* Younger or older than inclusion criteria,\n* Pregnant or breastfeeding\n* Women of childbearing potential unwilling to use highly effective contraceptive (see Risk section),\n* Confirmed or suspected renal, renovascular or endocrine causes of secondary hypertension,\n* Treatment with agents known to increase BP (e.g., adrenergic agonists for ADHD, SSRI and SNRI antidepressants, chronic use of decongestants or non-steroidal anti-inflammatory drugs,\n* Active or ongoing infection, including HIV\u002FAIDS,\n* Active or ongoing malignancy with the exception of basal cell carcinoma of the skin,\n* Severe psychiatric disorders,\n* Any condition that may alter the immunological results of the study including rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis, giant cell arteritis, psoriasis, inflammatory bowel disease, and multiple sclerosis,\n* Use of glucocorticoids, immunosuppressants, direct immunomodulators or chemotherapeutic drugs that in the judgment of the investigators may include a major inflammatory component,\n* Individuals who have contraindications to high salt diets (e.g. heart, renal, or liver failure) or low salt diets (e.g. postural orthostatic tachycardia syndrome, prescribed salt tablets, fludrocortisone or midodrine) or 24-hr ambulatory blood pressure monitoring (e.g. women with bilateral upper extremity lymphedema following breast cancer surgeries),\n* Prior diagnosis of liver cirrhosis or the following abnormal liver function studies: AST or ALT \\>1.5x the upper limit of normal or total bilirubin ≥1.5 mg\u002Fdl,\n* Use of Aspirin,\n* Use of monoamine oxidase inhibitors (MAO-I),\n* Individuals with medical contraindications to certain food content,\n* Use of nitrate therapy. (Participants who are taking PDE-5 inhibitors will be instructed to discontinue use at least 48 hours prior to testing),\n* Patients with resistant hypertension, defined as above-goal blood pressure despite the concurrent use of three antihypertensive drug classes at screening, will be excluded for safety reasons,\n* Average of three office-based blood pressure readings greater than 160 mmHg systolic or 100 mmHg diastolic will not be eligible for enrollment,\n* Use of drugs such as anticoagulants (e.g., warfarin), beta-blockers, antiarrhythmics, antidepressants\u002Fantipsychotics, and other medications primarily metabolized by CYP2C9, CYP2C19, and CYP2D6 that may cause drug-drug interaction.",{"count":140,"type":22},[381],"PHASE2","Hypertension is the leading cause of preventable deaths globally, driven by complications such as myocardial infarction, stroke, heart failure, and kidney disease. Recent updates in hypertension classification by the American Heart Association (AHA) place nearly half of the U.S. population in the hypertensive category. Excess dietary salt is a major risk factor for hypertension, with 50% of hypertensive individuals exhibiting salt-sensitivity of blood pressure (SSBP). SSBP is an independent predictor of cardiovascular events and death. While kidney mechanisms in salt-sensing have been extensively studied, emerging evidence suggests that immune cells can also sense sodium (Na+).\n\nThis trial hypothesizes that myeloid cell-derived isolevuglandins (IsoLGs) drive endothelial dysfunction, perpetuating the salt-sensitive phenotype. Preliminary data indicate that targeting IsoLGs with the IsoLG scavenger 2-hydroxybenzylamine (2-HOBA) may interrupt this immune-vascular axis, reducing salt sensitivity and associated cardiovascular risks.\n\nThis phase 2 clinical trial aims to investigate the role of 2-HOBA in modulating immune cell function within blood vessels in hypertensive patients. The study will explore the impact of immunity on salt sensitivity and assess 2-HOBA's potential to reduce endothelial dysfunction, improve immune cell activation, and alleviate SSBP.",[384,385,28,386],"Salt Sensitivity of Blood Pressure","High Blood Pressure","Renin-Angiotensin-Aldosterone System",[388,389,390,391],"salt sensitivity","hypertension","renin-angiotensin-aldosterone system","immune cells","2026-05-20",{"date":394,"type":33},"2026-05-26",{"date":99,"type":22},{"date":397,"type":22},"2031-07",{"name":399,"class":40},"Vanderbilt University Medical Center",{"id":401,"slug":402,"hasResults":12,"nctId":403,"briefTitle":404,"officialTitle":405,"acronym":406,"eligibilityCriteria":407,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":408,"enrollmentInfo":409,"targetDuration":4,"studyType":52,"phases":411,"briefSummary":412,"conditions":413,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":419,"lastUpdatePostDateStruct":420,"startDateStruct":422,"completionDateStruct":424,"leadSponsor":426,"locationsCount":41},"100638745","light-therapy-to-improve-sleep-in-tbi-sleep-active-biomarkers-and-glymphatic-function-100638745","NCT07601841","Light Therapy to Improve Sleep in TBI: Sleep-active Biomarkers and Glymphatic Function","Light Therapy to Improve Sleep in Veterans With TBI: Sleep-active Biomarkers and Glymphatic Function","GLIMPSE-LION","All subjects must:\n\n1. Male and female; any race; 18-89 years of age.\n2. Be English speaking.\\*\n3. Be accessible via phone.\n4. Be non-decisionally impaired. Determined by assessing the subject's ability to verbalize their understanding of the protocol back to us during the informed consent process.\n5. Not have a history of macular degeneration.\n6. Not have a history of bipolar disorder.\n7. Not be currently using a lightbox or a negative ion generator.\n8. Not be a shift worker.\n9. Have a documented history of TBI via the Head Trauma Events Characteristics (HTEC) or OHIO conducted in accordance with VA\u002FDoD Clinical Practice Guidelines.88\n10. Present with self-reported sleep-wake disturbances.\n11. Remain clinically stable for current pharmacologic treatment related to depression\u002Fanxiety, sleep, and pain.\n12. MRI specific compatibility requirements:\n\n    * No pacemaker, wires, defribrillator or implanted heart valves\n    * No history of head surgery requiring aneurysm clips\n    * No history of other orthopedic or general surgery requiring the implantation of ferrous pins, joints, electric devices\u002Fpumps, or other foreign metal objects\n    * History of eye exposure to metal (unprotected welding\u002Fmetalworking\u002Fshrapnel) is allowable provided the participant screens negative for metal in the eyes on an orbital x-ray or is able to provide clinical documentation of having screened negative.\n    * No history of non-removable hearing aids, middle\u002Finner ear prosthesis, or dentures\n    * No history of claustrophobia; if unsure participant will be pre-screened in our mock scanner\n    * Not currently pregnant, breastfeeding, or have an implanted IUD. Participants who are unsure of their pregnancy status will be administered an hCG urine pregnancy test the day of their scan.\n    * Able to lay flat on their back comfortably without a thick pillow for an extended period of time.\n    * Shoulder width does not exceed width for safety fitting in the MRI bore.\n\n      * This study is limited to English-speaking participants because all assessments, interventions, and consent materials are currently validated and approved only in English. Expanding to other languages would require translation and psychometric validation, which are beyond the scope and budget of this study. This limitation is acknowledged and will be addressed in future research as resources permit. Finally, the study team is only fluent in English, making it infeasible to accurately consent or interact with non-English speakers without interpreting services which again is outside of the scope of this projects budget and timeline. Proceeding without formal translation services would risk miscommunication in informed consent, data collection, or participant support and thus protects participants informed consent and participant understanding.","89 Years",{"count":410,"type":22},300,[80],"This is a clinical trial designed to examine how improved sleep through morning bright light therapy is improving downstream key physiologic processes related to brain health, i.e., mitochondrial function, systemic inflammation, and glymphatic function. All proposed methodology is already approved in other IRB applications.",[414,415,416,417,418,28],"Sleep","Phototherapy","Glymphatic System","Mitochondrial Dynamics","Brain Injuries, Traumatic","2026-05-18",{"date":421,"type":33},"2026-05-22",{"date":423,"type":33},"2025-12-12",{"date":425,"type":22},"2030-09-30",{"name":427,"class":40},"Oregon Health and Science University",{"id":429,"slug":430,"hasResults":12,"nctId":431,"briefTitle":432,"officialTitle":433,"acronym":4,"eligibilityCriteria":434,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":435,"targetDuration":4,"studyType":52,"phases":436,"briefSummary":437,"conditions":438,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":442,"lastUpdatePostDateStruct":443,"startDateStruct":445,"completionDateStruct":447,"leadSponsor":448,"locationsCount":41},"100301209","impact-of-nmes-and-hpro-on-recovery-after-sah--pilot-study-100301209","NCT03201094","Impact of NMES and HPRO on Recovery After SAH- Pilot Study","Impact of Neuromuscular Stimulation and High Protein Nutritional Supplementation on Long-term Recovery After Aneurysmal Subarachnoid Hemorrhage.","Inclusion criteria:\n\n1. . Being diagnosed with aneurysmal SAH\n2. . Aneurysmal repair within 48 hours of ictus.\n3. . Age between 25 and 80 years old. (\\>=25 years old and \\\u003C=80 years old)\n4. . Expected stay in the NCCU \\> 72 hours.\n5. . Admission Hunt Hess Grade \\>=2.\n6. modified Fisher score \\>1.\n\nExclusion criteria:\n\n1. . Subjects diagnosed with SAH from trauma, rupture of an arteriovenous malformation, neoplasm, vasculitis, or other secondary causes;\n2. . Unlikely to survive one week post hemorrhage either due to impending brain death or likely request for withdrawal of care;\n3. . Unlikely to remain in the ICU for more than 7 days;\n4. . Body mass index \\\u003C 15 or \\>40 kg\u002Fm2;\n5. . Allergy to whey protein;\n6. . Evidence of lower extremity paresis or spasticity within 48 hours of injury\n7. . Pre-morbid modified Rankin Score \\>1.\n8. . Known pregnancy\n9. . Presence of active malignancy\n10. . Diagnosis of an inflammatory disorder\n11. . Presence of a neuromuscular disorder\n12. . Diagnosis of chronic renal insufficiency or acute kidney injury (GFR \\\u003C 30 mL\u002Fmin\u002F1.73m2)\n13. . Hepatic insufficiency defined as AST\u002FALT levels \\>2.5 above normal upper limits.\n14. . On-going seizure activity as assessed clinically or by electrographic detection on continuous electroencephalogram (cEEG) at time of enrollment\n15. . Prisoner.",{"count":78,"type":22},[80],"The study purpose is to investigate the hypothesis that in adults with SAH, early neuromuscular electrical stimulation (NMES) and high protein supplementation (HPRO) will improve muscle mass, metabolic and inflammatory biomarker profiles, compared to SAH controls receiving standard of care interventions for nutrition and mobilization. The investigators will accomplish this by studying the effects of a high protein (HPRO) nutritional treatment as well as NMES intervention have upon muscle wasting and motor strength acutely after SAH. This will be addressed in a prospective trial of SAH patients receiving HRPO with NMES as compared to age and severity-matched SAH patients undergoing standard of care interventions for nutrition and mobilization. Additionally, the study will investigate the impact HPRO and NMES interventions have upon inflammatory cytokines and markers of energy balance. Results of this study will establish evidence for precision nutrition plus early exercise to mitigate the catabolic and inflammatory state produced by SAH to improve muscle, metabolic, and health recovery outcomes.",[439,440,28,441],"Subarachnoid Hemorrhage","Muscle Atrophy","Nutritional and Metabolic Disease","2026-05-15",{"date":444,"type":33},"2026-05-19",{"date":446,"type":33},"2017-12-01",{"date":37,"type":22},{"name":449,"class":40},"University of Maryland, Baltimore",{"id":451,"slug":452,"hasResults":12,"nctId":453,"briefTitle":454,"officialTitle":454,"acronym":4,"eligibilityCriteria":455,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":456,"targetDuration":4,"studyType":52,"phases":457,"briefSummary":458,"conditions":459,"keywords":460,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":464,"lastUpdatePostDateStruct":465,"startDateStruct":466,"completionDateStruct":468,"leadSponsor":470,"locationsCount":41},"100586573","royal-jelly-as-a-strategy-to-modulate-inflammation-and-oxidative-stress-in-patients-with-systemic-arterial-hypertension-100586573","NCT06917131","Royal Jelly as a Strategy to Modulate Inflammation and Oxidative Stress in Patients With Systemic Arterial Hypertension","Inclusion Criteria:\n\n* Diagnosis of stage 1 hypertension\n* Regular treatment for more than 6 months\n* No changes in medication doses during the last 3 months\n\nExclusion Criteria:\n\n* Autoimmune diseases\n* Infectious diseases\n* Diabetes\n* Chronic kidney disease\n* Liver disease\n* Cancer\n* AIDS\n* Pregnant women\n* Use of catabolic drugs or antibiotics\n* Use of antioxidant vitamin supplements, prebiotics, probiotics, or synbiotics\n* Habitual intake of royal jelly\n* Allergy to bee stings\n* Acute myocardial infarction (AMI)\n* Stroke (CVA)",{"count":21,"type":22},[80],"The study aims to evaluate the effect of the royal jelly on inflammation and oxidative stress in participants with systemic arterial hypertension. A longitudinal double-blind randomized clinical trial will be carried out, involving hypertensive participants for two months.",[200,85,28],[461,462,200,463],"royal jelly","inflammation","cardiovascular diseases","2026-05-14",{"date":444,"type":33},{"date":467,"type":33},"2024-09-18",{"date":469,"type":22},"2026-12-10",{"name":471,"class":40},"Universidade Federal Fluminense",{"id":473,"slug":474,"hasResults":12,"nctId":475,"briefTitle":476,"officialTitle":476,"acronym":4,"eligibilityCriteria":477,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":478,"targetDuration":4,"studyType":52,"phases":480,"briefSummary":481,"conditions":482,"keywords":484,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":488,"lastUpdatePostDateStruct":489,"startDateStruct":490,"completionDateStruct":491,"leadSponsor":493,"locationsCount":41},"100640154","ginger-in-the-modulation-of-inflammatory-cytokines-and-oxidative-stress-in-patients-with-coronary-artery-disease-100640154","NCT07596979","Ginger in the Modulation of Inflammatory Cytokines and Oxidative Stress in Patients With Coronary Artery Disease","Inclusion Criteria:\n\n* Both sexes\n* Over 18 years of age;\n* Diagnosed with Coronary Artery Disease: confirmed by coronary angiography, coronary computed tomography angiography, or functional testing with ischemic load);\n* Participants who are asymptomatic or have angina limited to functional class III will be considered;\n* Patients who have already undergone coronary revascularization and angioplasty may participate;\n* the last acute coronary event must have occurred more than one year ago.\n\nExclusion Criteria:\n\n* Unstable Coronary Artery Disease;\n* Pre-operative coronary artery bypass grafting or awaiting elective angioplasty;\n* Unstable angina;\n* NYHA functional class III or higher;\n* Advanced chronic kidney disease (creatinine clearance \\\u003C 30 ml\u002Fmin\u002F1.73 m²);\n* Individuals with autoimmune diseases.",{"count":479,"type":22},50,[80],"The study aims to evaluate the effect of ginger supplementation on inflammatory cytokines and markers of oxidative stress in patients with Coronary Artery Disease (CAD). A longitudinal double-blind randomized clinical trial will be carried out, involving CAD participants for two months.",[483,27,28],"Coronary Artery Disease (CAD)",[485,486,462,487],"ginger","coronary artery disease","oxidative stress","2026-05-12",{"date":444,"type":33},{"date":419,"type":22},{"date":492,"type":22},"2028-12",{"name":471,"class":40},{"id":495,"slug":496,"hasResults":12,"nctId":497,"briefTitle":498,"officialTitle":498,"acronym":4,"eligibilityCriteria":499,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":500,"targetDuration":4,"studyType":52,"phases":502,"briefSummary":503,"conditions":504,"keywords":506,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":488,"lastUpdatePostDateStruct":508,"startDateStruct":509,"completionDateStruct":511,"leadSponsor":513,"locationsCount":41},"100639653","effects-of-propolis-and-royal-jelly-supplementation-on-inflammatory-and-oxidative-stress-markers-in-patients-with-systemic-arterial-hypertension-100639653","NCT07596966","EFFECTS OF PROPOLIS AND ROYAL JELLY SUPPLEMENTATION ON INFLAMMATORY AND OXIDATIVE STRESS MARKERS IN PATIENTS WITH SYSTEMIC ARTERIAL HYPERTENSION","Inclusion Criteria:\n\n* Diagnosis of stage 1 and 2 hypertension\n* Regular treatment for more than 6 months\n* There have been no changes in medication doses over the last three months.\n\nExclusion Criteria:\n\n* Autoimmune and infectious diseases, diabetes\n* Chronic kidney disease, liver disease, cancer and AIDS\n* Pregnant women\n* Use of catabolic drugs or antibiotics\n* Use of antioxidant vitamin supplements, prebiotics, probiotics, symbiotic\n* Habitual intake of royal jelly and propolis",{"count":501,"type":22},48,[80],"The study aims to evaluate the effect of the royal jelly and propolis on inflammation and oxidative stress in participants with systemic arterial hypertension. A longitudinal double-blind randomized clinical trial will be carried out, involving hypertensive participants for two months.",[505,28],"Systemic Arterial Hypertension",[462,461,507,389,487],"propolis",{"date":444,"type":33},{"date":510,"type":33},"2025-10-15",{"date":512,"type":22},"2027-12-10",{"name":471,"class":40},{"id":515,"slug":516,"hasResults":12,"nctId":517,"briefTitle":518,"officialTitle":519,"acronym":4,"eligibilityCriteria":520,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":166,"enrollmentInfo":521,"targetDuration":4,"studyType":52,"phases":522,"briefSummary":523,"conditions":524,"keywords":527,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":488,"lastUpdatePostDateStruct":530,"startDateStruct":531,"completionDateStruct":533,"leadSponsor":535,"locationsCount":41},"100637286","red-propolis-supplementation-as-a-strategy-in-chronic-kidney-disease-100637286","NCT07597005","Red Propolis Supplementation as a Strategy in Chronic Kidney Disease","Red Propolis as a Strategy to Modulate Inflammation and Oxidative Stress in Patients With Chronic Kidney Disease","Inclusion Criteria:\n\n* patients with CKD stages 3-5 under conservative management\n\nExclusion Criteria:\n\n* pregnant,\n* lactating,\n* smoker\n* patients using antibiotics and antioxidant supplements in the last three months\n* patients with autoimmune and infectious diseases,\n* patients with cancer, liver disease, and AIDS",{"count":51,"type":22},[80],"The objective of this study is to evaluate the effects of red propolis on inflammation and oxidative stress in patients with chronic kidney disease on conservative management.",[525,27,526,28],"Kidney Disease","Chronic Kidney Disease",[487,528,462,529],"red propolis","chronic kidney disease",{"date":444,"type":33},{"date":532,"type":33},"2025-09-30",{"date":534,"type":22},"2027-08-31",{"name":471,"class":40},{"id":537,"slug":538,"hasResults":12,"nctId":539,"briefTitle":540,"officialTitle":540,"acronym":4,"eligibilityCriteria":477,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":541,"targetDuration":4,"studyType":52,"phases":542,"briefSummary":543,"conditions":544,"keywords":545,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":488,"lastUpdatePostDateStruct":546,"startDateStruct":547,"completionDateStruct":548,"leadSponsor":549,"locationsCount":41},"100640646","effects-of-royal-jelly-and-propolis-on-metabolomic-signatures-inflammation-and-cardiovascular-risk-in-patients-with-coronary-artery-disease-100640646","NCT07596992","Effects of Royal Jelly and Propolis on Metabolomic Signatures, Inflammation, and Cardiovascular Risk in Patients With Coronary Artery Disease.",{"count":479,"type":22},[80],"The aim of this project is to evaluate the effect of bioactive compound sources, propolis and royal jelly, on metabolomics, inflammation, and cardiovascular risk markers in participants with coronary artery disease. A longitudinal double-blind randomized clinical trial will be carried out, involving CAD participants for two months.",[483,27,28],[461,507,486,487,462],{"date":444,"type":33},{"date":419,"type":22},{"date":492,"type":22},{"name":471,"class":40},{"id":551,"slug":552,"hasResults":12,"nctId":553,"briefTitle":554,"officialTitle":555,"acronym":556,"eligibilityCriteria":557,"healthyVolunteers":136,"sex":17,"minAge":18,"maxAge":558,"enrollmentInfo":559,"targetDuration":4,"studyType":52,"phases":561,"briefSummary":562,"conditions":563,"keywords":565,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":488,"lastUpdatePostDateStruct":572,"startDateStruct":573,"completionDateStruct":574,"leadSponsor":576,"locationsCount":578},"100637926","mitigating-mitochondrial-rna-release-during-aging-to-control-inflammation-and-senescence-100637926","NCT07596615","Mitigating Mitochondrial RNA Release During Aging to Control Inflammation and Senescence","Mitigating Mitochondrial RNA Release During Aging to Control Inflammation and Senescence, Preserving Organ Function and Enhancing Healthspan","MIRACLE","Inclusion Criteria:\n\n* Male and female\n* Age between 18 and 90 years (stratified in three groups: young, middle-aged, elderly)\n* Written informed consent\n\nExclusion Criteria:\n\n* Inability to understand the potential risk and benefits of the study\n* Legal incapacity\n* Subjects who have taken antibiotics, anti-inflammatory drugs, or antihistamines within the past 7 days\n* Diagnosis of diabetes mellitus\n* Use of anticoagulant medications\n* Any subject with a contraindication to the mini-invasive biopsy procedure","90 Years",{"count":560,"type":22},90,[80],"The MIRACLE study aims to investigate age-related mitochondrial dysfunction, mitochondrial RNA (mtRNA) release, inflammation, and cellular senescence in adult participants across three age groups. Skin-derived fibroblasts and peripheral blood mononuclear cells (PBMCs) will be isolated from skin biopsy and blood samples to characterize age-related cellular and molecular changes and to test experimental therapeutic strategies identified in preclinical studies. Serum, plasma, and whole-blood RNA will be used for protocol-defined analyses of circulating inflammatory mediators and systemic transcriptional signatures related to inflammation, type I interferon activation, mitochondrial stress response, immune aging, and senescence-associated pathways.",[201,28,564],"Healthy Ageing",[566,567,568,569,570,571],"mitochondrial dysfunction","skin-derived fibroblasts","mtRNA","PBMCs","senescence","inflammaging",{"date":444,"type":33},{"date":369,"type":22},{"date":575,"type":22},"2031-09",{"name":577,"class":40},"Mario Negri Institute for Pharmacological Research",2,{"id":580,"slug":581,"hasResults":12,"nctId":582,"briefTitle":583,"officialTitle":583,"acronym":4,"eligibilityCriteria":584,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":585,"targetDuration":4,"studyType":52,"phases":586,"briefSummary":587,"conditions":588,"keywords":591,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":488,"lastUpdatePostDateStruct":594,"startDateStruct":595,"completionDateStruct":597,"leadSponsor":599,"locationsCount":41},"100530171","effects-of-nattokinase-on-inflammation-and-cardiovascular-risk-markers-in-patients-with-dyslipidemia-100530171","NCT06183307","Effects of Nattokinase on Inflammation and Cardiovascular Risk Markers in Patients With Dyslipidemia","Inclusion Criteria:\n\n* Both sexes;\n* Over 18 years of age;\n* Isolated increase in LDL-c (LDL-c ≥ 160 mg\u002FdL);\n* Isolated increase in triglycerides (TG ≥ 150 mg\u002FdL or ≥ 175 mg\u002FdL, without fasting);\n* increased LDL-c (LDL-c ≥ 160 mg\u002FdL)\n* TG (TG ≥ 150 mg\u002FdL or ≥ 175 mg\u002FdL, without fasting);\n* Reduction in HDL-c (men \\\u003C 40 mg\u002FdL and women \\\u003C 50 mg\u002FdL) alone or in association with an increase in LDL-c or TG. If TG ≥ 400 mg\u002FdL.\n* Individuals who are already using lipid-lowering therapy (statins or non-statins) will also be included.\n\nExclusion Criteria:\n\n* Participants with autoimmune and infectious diseases, diabetes, cancer and AIDS;\n* Pregnant women;\n* Participants using catabolic drugs or antibiotics\n* Participants on anticoagulant medication\n* Participants using antioxidant vitamin supplements, prebiotic, probiotic or synbiotic and who are allergic to corn or soy starch.",{"count":501,"type":22},[80],"The study aims to evaluate the effect of the nattokinase enzyme on inflammation and markers of cardiovascular risk in participants with dyslipidemia. A longitudinal double-blind randomized clinical trial will be carried out, involving hypertensive participants with dyslipidemia for two months.",[589,590,28],"Cardiovascular Diseases","Dyslipidemias",[592,589,28,593],"nattokinase","fibrinogen",{"date":464,"type":33},{"date":596,"type":33},"2024-08-03",{"date":598,"type":22},"2026-12-20",{"name":471,"class":40},{"id":601,"slug":602,"hasResults":12,"nctId":603,"briefTitle":604,"officialTitle":605,"acronym":606,"eligibilityCriteria":607,"healthyVolunteers":136,"sex":269,"minAge":18,"maxAge":4,"enrollmentInfo":608,"targetDuration":4,"studyType":52,"phases":610,"briefSummary":611,"conditions":612,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":488,"lastUpdatePostDateStruct":615,"startDateStruct":616,"completionDateStruct":618,"leadSponsor":620,"locationsCount":41},"100456905","stress-phenotypes-and-preterm-birth-100456905","NCT05229666","Stress Phenotypes and Preterm Birth","Stress Phenotypes and Preterm Birth: Immune and Energetic Cellular Dysregulation and the Preventive Effect of Social Support","PTB","Inclusion Criteria\n\n* Pregnant women 18 years of age or older (based on self-report)\n* Not currently smoking, drinking alcohol, or taking drugs (based on self-report)\n* Planning to deliver at CUIMC\u002FNYP (based on self-report)\n* In the first or second trimester of pregnancy (prior to 28 weeks gestation) (based on self-report of estimated date of delivery)\n\nExclusion Criteria\n\n* Multi-fetal pregnancy (based on self-report)\n* Taking medications regularly that affect the cardiovascular and inflammatory systems, including NSAIDS and other anti-inflammatories, α blockers, β blockers, corticosteroids, chronic-use asthma medications (e.g. beta2- adrenoceptor agonists) (based on self-report)\n\n  * This does NOT include baby aspirin or low-dose aspirin, as baby aspirin \u002F low-dose aspirin is not normally considered to be an NSAID.\n* Inflammatory conditions including rheumatoid arthritis, lupus, and multiple sclerosis (based on self-report)",{"count":609,"type":22},200,[80],"Pregnancy ends in preterm birth (PTB) for approximately 1 in 10 women, though more often for Non-Hispanic Black women, 14.12% PTB rate, compared to 9.09% for Non-Hispanic White women. Psychosocial stress and childhood trauma each are associated with risk for PTB and PTB has an intergenerational impact: mothers born preterm are more likely to give birth preterm, especially amongst Black women. In this project, we will study mitochondria, which contain their own genome, the mitochondria DNA, and are inherited from the mother, as they represent a potential intersection point between psychosocial experiences and their biological embedding in underlying disease outcomes such as PTB",[613,28,306,614],"Preterm Birth","Mental Health Issue",{"date":464,"type":33},{"date":617,"type":33},"2021-12-09",{"date":619,"type":22},"2027-12",{"name":621,"class":40},"Columbia University",{"id":623,"slug":624,"hasResults":12,"nctId":625,"briefTitle":626,"officialTitle":627,"acronym":628,"eligibilityCriteria":629,"healthyVolunteers":136,"sex":17,"minAge":630,"maxAge":631,"enrollmentInfo":632,"targetDuration":4,"studyType":52,"phases":633,"briefSummary":634,"conditions":635,"keywords":640,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":644,"lastUpdatePostDateStruct":645,"startDateStruct":646,"completionDateStruct":647,"leadSponsor":649,"locationsCount":41},"100616740","mediterranean-diet-uptake-and-nutrition-on-child-health-inflammation-and-early-life-symbiosis-munchies-study-100616740","NCT07309536","Mediterranean Diet Uptake and Nutrition on Child Health, Inflammation, and Early-life Symbiosis (MUNCHIES) Study","Mediterranean Diet Uptake and Nutrition on Child Health, Inflammation, and Early-life Symbiosis (MUNCHIES): A Randomized Controlled Trial","MUNCHIES","Inclusion Criteria:\n\n* Parent is ≥19 years of age.\n* Carried a singleton pregnancy.\n* Delivered at term (≥37 weeks gestation).\n* Delivered vaginally or by cesarean section.\n* Infant was born with a birth weight between 2,500 g and 4,500 g.\n* Toddler is between 24 and 36 months of age at enrollment.\n* Parent is able to communicate in English.\n* Parent is willing to adhere to the Mediterranean diet for their toddler for 3 weeks.\n* Parent is willing to participate in a nutrition education program for 3 months.\n* Parent is willing to complete all measurements and provide a stool sample from their toddler.\n\nExclusion Criteria:\n\n* Toddler has food allergies or dietary restrictions (e.g., gluten-free) that make it difficult to follow a Mediterranean diet.\n* Toddler is at high risk for food allergies (e.g., strong family history of multiple food allergies common to the Mediterranean diet).\n* Toddler is already following a Mediterranean diet.\n* Toddler has had recent or active consumption of antibiotics, probiotics, or prebiotic drops.\n* Toddler has an active acute illness, such as fever, diarrhea, or constipation.\n* Toddler was born with a congenital illness or malformation that could affect diet, inflammation, gut health, or body composition.\n* Toddler is currently breastfeeding, formula-feeding, or combination feeding.","24 Months","36 Months",{"count":51,"type":22},[80],"Toddlerhood (ages 2-3) is a critical window when the gut microbiome is still developing and eating habits are being established. Yet, many Canadian toddlers eat diets high in sugar and salt, which may affect long-term health. This study will test whether a MED diet can improve dietary inflammation, gut health, and body composition in toddlers and whether a tailored nutrition education program for parents can help families maintain healthy eating patterns.\n\nIn this study, toddlers will be randomly assigned to a 3-week MED diet or their usual diet. Families in the MED diet group will receive free meal boxes for the 3 weeks, plus guidance from a nutrition researcher through a structured education program. The standard diet group will continue their regular diet with general nutrition advice. Researchers will collect dietary information, body composition assessments, and stool samples to measure gut microbiome composition and metabolites.\n\nThis first study of a controlled diet intervention in toddlers, combining behavioral support, high-quality food provision, and advanced gut microbiome analysis, will help understand how early diet shapes lifelong eating habits and health, guiding public health strategies and precision nutrition approaches to prevent chronic disease from early life.",[636,637,638,639,28],"Gut Microbiome","Body Composition","Adherence","Metabolites",[641,642,643,28],"Dietary patterns","Gastrointestinal microbiome","Body composition","2026-05-11",{"date":488,"type":33},{"date":97,"type":22},{"date":648,"type":22},"2027-11-01",{"name":650,"class":40},"University of New Brunswick"]